RAD51C and ovarian carcinoma: In addition, RAD51C methylation appears to be a positive predictive biomarker of PARP inhibitor response in ovarian carcinomas, where loss of methylation even in one copy of the gene is sufficient to confer resistance to this inhibitor [69].